

Table 5.6i
Immunosuppression Use for Antirejection Treatment from Transplant
to One Year Following Transplantation, 1997 to 2006
Recipients with Kidney Transplants

	Year of Transplant									
	1997	1998	1999	2000	2001	2002	2003	2004	2005	2006
Transplants	11,703	12,452	12,760	13,613	14,266	14,779	15,137	16,004	16,482	17,091
Tx with Antirejection Treatments	3,438	2,649	2,444	2,378	2,391	2,177	1,972	1,863	1,701	1,582
Antibodies										
Any in Category	27.2%	37.0%	37.1%	35.6%	37.7%	38.8%	48.7%	48.1%	39.4%	45.3%
Atgam/NRATG/NRATS	6.6%	8.1%	6.0%	2.9%	2.5%	2.3%	1.8%	1.1%	1.4%	1.5%
OKT3	21.6%	26.2%	18.8%	14.6%	11.8%	10.8%	9.0%	7.7%	5.5%	4.4%
Thymoglobulin	0.2%	1.0%	7.9%	13.0%	18.2%	23.8%	31.9%	33.1%	28.1%	33.6%
Zenapax	0.2%	3.4%	5.8%	3.4%	2.9%	1.9%	3.1%	3.3%	0.7%	1.6%
Simulect	0.0%	0.3%	1.6%	4.0%	5.0%	3.4%	5.6%	4.8%	4.2%	5.1%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.2%	1.4%	1.5%	1.9%	0.7%
Corticosteroids										
Any in Category	58.7%	78.7%	78.4%	80.1%	80.1%	79.7%	72.0%	70.5%	75.5%	73.3%
Steroids	58.7%	78.7%	78.4%	80.1%	80.1%	79.7%	72.0%	70.5%	75.5%	73.3%
Antimetabolites										
Any in Category	0.5%	0.1%	0.1%	0.3%	0.2%	0.1%	0.2%	0.5%	0.2%	0.1%
Cytoxin	0.3%	0.1%	0.1%	0.3%	0.1%	0.1%	0.2%	0.4%	0.2%	0.1%
Methotrexate	0.2%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.0%	0.0%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Individual drug percentages will not necessarily add up to the drug category percentages, as patients may be prescribed more than one drug within the same category.